Life Sciences M&A Trends in 2026
Key Takeaways:
- Life sciences M&A is rebounding to a more favorable environment in 2026, with higher-value, strategic deals offsetting lower overall deal volume.
- The patent cliff is acting as a catalyst for big pharma to focus on acquiring growth-focused assets and late-stage pipelines, rather than relying on long-risk R&D.
- AI, digital transformation, and consumer-centric care are reshaping deals, with many transactions targeting AI-enabled platforms and data-driven innovation.
- Resourcing and workforce planning are becoming more critical as talent scarcity and M&A-driven attrition/displacement puts pressure on companies to fill roles.
The life sciences industry is no stranger to peaks and troughs in mergers and acquisitions (M&A) trends, particularly in the post-pandemic era. However, after a dip in 2023, factors seem to be influencing a more optimistic, favorable M&A environment.
As we continue to move through 2026, industry stakeholders need to understand the factors influencing these deals and the way they impact the supply of highly-skilled talent in the life sciences sector.
The Current Life Sciences M&A Outlook
Despite volatility due to evolving global trade policies and higher interest rates, the total deal value in the life sciences industry reached $372bn in 2025 (an increase of 47% year-over-year), with the Americas accounting for 73% of the total and dominating in terms of deal value.
Though overall deal volume is lower, there has been a shift instead to higher-impact, strategic transactions instead, driven by life sciences companies seeking to overcome the drawn-out timelines and high-risk nature of R&D.
Between biotechnology, pharmaceutical, and medtech companies, the contribution to M&A’s uptick has been relatively equal (about 30% of deal volume). Biopharmaceuticals in particular have been characterized by growth-focused M&A — between 2020 and 2025, 76% of deals were focused on growth, compared to 34% a decade ago. MedTech has entered into 2026 with a healthier M&A environment due to improved financing conditions and sector resilience.
Pipeline pressures continue to influence life sciences M&A trends, as businesses look to navigate evolving regulatory requirements causing a “patent cliff” for large pharma, in which a revenue risk of $300bn in annual branded drug revenue is at risk of being lost to generic and biosimilar competition between 2025-2030.
Key M&A Life Sciences Deal Activity
- Johnson & Johnson acquired Intra-Cellular Therapies, Inc in Q2 2025 for $14.6bn, with particular emphasis on CAPLYTA®, a schizophrenia and bipolar disorder drug.
- Novartis acquired Avidity Biosciences in Q1 2026 for $12bn, aiming to strengthen Novartis’ late-stage neuroscience pipeline.
- Pfizer acquired obesity biotech Metsera for up to $10bn in November 2025, following a surprise bid from Novo Nordisk, with additions to their pipeline including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist.
- Merck & Co. acquisition of Verona Pharma announced in Q4 2025, valued at $10bn and boosting Merck’s respiratory portfolio, centered on Ohtuvayre, a maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD).
- Novo Nordisk acquired Akero Therapeutics in October 2025 for up to $5.2bn, and its metabolic dysfunction-associated steatohepatitis (MASH) candidate efruxifermin.
These acquisitions represent the significant reshaping of big pharma portfolios, specifically in relation to the “patent cliff”, alongside the rebound of global deal activity towards larger-scale, high-impact deals — as with 2025 mergers and acquisitions of note, addressing unmet medical needs is still a key focus of many transactions.
The Trends Impacting Life Sciences M&A
Patent cliffs in biologics pharma driving diversification
The patent cliff wave has continued to impact life sciences mergers and acquisitions, with a cluster of widely prescribed small-molecule drugs set to lose protection in 2026 across primary care, cardiology, and immunology, pushing companies to favor lower-cost versions to reduce revenue risk.
A 2024 annual report by Merck noted the pressure points facing Keytruda, a prescription immunotherapy medication. It expects U.S. sales to decline in January 2028 with government pricing under the Inflation Reduction Act, then further decline after a loss of exclusivity due to the expiration of the U.S. compound patent in 2028. This is just one example of how originators attempt to hold share when a biologic is on the approach to losing exclusivity.
Consumer-centric, Tech-enabled care
M&A is one of the fastest ways to catalyze digital innovation, and the deals that stand out in the future will be those backed by AI-enhanced productivity, differentiated data, evidence-backed innovation, and clear pathways to long-term value creation.
An example of the high-innovation shift in life sciences M&A was one of medtech’s largest ever AI deals in GE HealthCare’s $2.3bn acquisition of Intelerad, aimed at accelerating GE HealthCare’s D3 strategy (disease-focused devices enabled by digital and AI).
Therapeutic Focus That Sets Standards of Care
Areas such as cardiometabolic, CNS, oncology, and immunology are still maintaining a strong pace of innovation which continues to drive financial and strategic interest for capital allocation. According to a KPMG study, oncology and immunology are anticipated to be the most competitive areas for acquisition by biopharma professionals.
In pharma in 2025, oncology was at the top of dealmaking with 30% of $120bn deals, with buyers focusing on immune cell therapies, multi-specific antibodies, and radioligand technologies, while neurology, rare disease, and cardiovascular drove $36bn in transactions.
Technological innovation and digital transformation are also key areas across subsectors, with 90% of medical devices respondents expecting 10% or more of deals to incorporate artificial intelligence or machine learning. AI-driven analytics, robotics platforms, and connected-care ecosystems are prioritized targets, acting as deal catalysts.
Portfolio Optimization
In 2025, a number of key markers have impacted deal activity and the shaping of portfolios, including:
- A shift toward acquisitions of single or smaller portfolios of clinical assets
- An emphasis on acquiring mature, high-growth technologies in medtech
- The absence of mega-deals, particularly in healthcare, driving a shift toward operational optimization and risk management
In short, acquisitions are becoming more strategic and specific to address gaps, further innovation, and strengthen growth after a period of economic uncertainty.
What to Expect in Life Sciences M&A For the Rest of 2026
The outlook for life sciences M&A activity in 2026 is favorable — a combination of fast transformation and a surge of higher-value deals make 2026 a year of capitalizing on innovation. In a KPMG study, 67% of respondents expected more deals in 2026 than 2025, with a higher percentage anticipating growth in deal volume rather than fewer transactions.
A few of the trends we expect to see include:
- Urgency to restock pipelines: The patent cliff will drive pharma companies to double their efforts to develop or acquire the next generation of top-selling medications.
- Strong financial capacity for M&A: Industry leaders should have considerable financial resources to make more strategic acquisitions, given that in 2025, 23 companies had a combined cash and debt capacity of nearly $1.4 trillion.
- Artificial intelligence: AI is an emerging catalyst for M&A activity, as AI-powered platforms transform drug discovery, clinical trial management, and administrative operations, with many looking to fully integrate these capabilities.
- Regulatory changes: The broader life sciences regulatory environment is driving the portfolio shift towards high-value, strategic assets rather than relying on internal R&D pipelines, and deal complexities and timelines are likely to be impacted by regulatory changes.
What This Means for Resourcing and Workforce Planning in Life Sciences
An optimistic M&A outlook in the life sciences industry goes hand-in-hand with a more competitive market for finding resourcing solutions and workforce planning. The demand created by the M&A market is influencing a demand for specialized support to secure those with regulatory, tech-enabled, and commercial skillsets.
During M&A changeovers, attrition and displacement can cause turbulence as employees consider their options and overall job security, increasing turnover rates and creating further strain on companies during an already challenging time.
Scarcity of talent is driving more strategic workforce planning, particularly as the life sciences industry continues to experience periods of highs and lows in growth of employment. Whilst U.S. life sciences employment reached a record of 2.1 million in March 2025, it fell measurably in April 2025, as high competition and layoffs are still impacting the industry, making partnering with a consultancy firm highly advantageous for businesses looking to be more strategic and adaptable.
Partner With Us: Your Leading Life Sciences Consulting Firm
Redbock is a leading , providing FSP and contract resourcing solutions that help businesses through challenging M&A transition periods. We align customized solutions to your business post-merger, ensuring that our solutions help you onboard and retain skilled professionals when you need them most to thrive in the ever-changing, competitive life sciences market.
If your organization is looking for highly skilled life sciences consultants to support your business during a period of change, contact us today to navigate the transition and future changes with confidence.
Frequently Asked Questions: Life Sciences M&A
What top trends are shaping life sciences M&A activity in 2026?
The top trends impacting life sciences M&A activity in 2026 are: the patent cliffs, driving more strategic and high-quality deals to fill pipeline gaps; digital transformation, with an emphasis on deals backed by AI-enhanced productivity; therapeutic focus areas continuing to drive deals, including cardiometabolic, CNS, oncology, and immunology.
Regulatory and policy changes are also catalyzing portfolio restructuring, and deal activity is rooted in strategy rather than simply just buying assets to meet these new demands and developments.
Which life sciences companies have been most involved in recent M&A deals?
- Johnson & Johnson: Acquired Intra-Cellular to strengthen its neuroscience portfolio.
- Merck: Bought Verona Pharma for respiratory growth, adding Ohtuvayre to its lineup.
- Pfizer: Acquired Metsera to build their portfolio in the obesity and cardiometabolic pipeline.
- Novartis: Agreed to acquire Avidity Biosciences to improve its RNA drug-delivery capability and strengthen its late-stage neuroscience pipeline.
What are the most common post-merger integration challenges in life sciences?
Some of the biggest post-merger integration challenges in life sciences are operational disruption, cultural misalignment, failure to meet financial targets, IT integration difficulties, loss of key talent, and low morale, according to a Travelers report.
What should I look for when selecting a life sciences consulting partner?
A good life sciences consulting partner should bring extensive industry experience, regulatory and compliance knowledge, and sector-specific awareness of the challenges in the current life sciences hiring market to the table. Supports should be tailored to your specific subsector and practical processes (e.g., integrating teams, or supporting day-one execution after a deal).